$SN

Shah Neil B. sold $5.5M of SN

Shah Neil B. (Chief Commercial Officer) sold 29,667 shares of SharkNinja, Inc. (SN) at an average of $186.76 ($186.67–$187.07, $5.54M total) across 2 trades on 2026-08-07.

Original reporting
SEC EDGAR · Shah Neil B.
Published Aug 8, 2026, 12:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 12:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SN
Neutral
medium confidence
Mentioned
$SN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNNeutralLow
01

Why it matters

A $5.54M open-market sale by a senior commercial officer is disclosed, but the filing contains no new guidance, earnings, legal, or product information.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no new fundamental catalyst in the text.

03

What to watch

The article does not state motivations, option exercises, or whether other insiders filed offsetting buys; one sale is not enough to infer a trend.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after-hours; sale executed 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for SharkNinja, Inc. (SN).

Company-level read

Ticker impact

$SNNeutralMedium confidence
Context

SharkNinja insider Shah Neil, Chief Commercial Officer, sold 29,667 shares in open-market trades totaling about $5.54M on 2026-08-07.

Expected impact

Likely limited near-term impact; treat as sentiment noise unless follow-on filings show sustained selling or other disclosures emerge.

Evidence & confidence

The filing provides transaction size, price range, and post-sale holdings, but no operational, financial, or regulatory catalyst for SN is included.

Market effects

No sector-level signal; insider sales are common and typically do not re-rate consumer/household or appliance peers without accompanying fundamentals.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be misread as bearish; insiders may sell for diversification, taxes, or planned liquidity needs unrelated to outlook.

Key entities

  • SharkNinja, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Shah Neil B.

    Chief Commercial Officer who sold 29,667 shares on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SNHighAI 8/10

Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports

Smith & Nephew's merger talks with Johnson & Johnson's orthopaedics unit collapsed over disagreement on the CEO role, according to the Financial Times. The deal would have valued the unit at up to $22 billion, nearly double Smith & Nephew's market cap. Both companies were aligned on financial terms but disagreed on leadership. Smith & Nephew's former CEO left in 2019 over pay demands.

$SNMed

UBS sees attractive risk/reward in three European medtech into Q3 results

UBS identifies Convatec, Smith & Nephew, and Sonova as attractive European medtech stocks ahead of Q3 results, citing revenue and earnings growth expectations. Convatec is expected to report 6% organic growth, Smith & Nephew may undergo a strategic review, and Sonova could raise guidance due to market growth and currency tailwinds. UBS provides price targets for each company.

$SNHighAI 8/10

Blowout Guidance Sends SharkNinja Shares Higher

SharkNinja (SN) reported Q2 2026 net sales of $1.77B (up 22.2% YoY) and adjusted net income of $178M (up 29%). The company raised full-year 2026 guidance, targeting up to 17% sales growth and $6.55 adjusted EPS. SN shares have risen 56% YTD, supported by institutional demand and strong fundamentals, including 3-year sales growth of 20% and EPS growth of 63.8%.

$SNMed

UBS raises SharkNinja stock price target to $219 on product expansion

UBS raised its price target for SharkNinja (NYSE:SN) to $219.10 from $147 and kept a Buy rating, citing Q2 results and faster product launches. The firm pointed to 13 new products year to date versus nine in the first eight months of 2025, plus plans for up to three new subcategories in 2026. SN trades at $187.68 and reported revenue of $1.77B (+22.2%) with adjusted EPS of $0.92.